Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [4]. Core Insights - The company has signed a strategic research and development collaboration agreement with AstraZeneca, granting AstraZeneca exclusive global rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects. The company will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty on net sales [1][2]. - The collaboration marks an upgrade from single product licensing to platform licensing, reflecting AstraZeneca's strong recognition of the company's long-acting peptide and AI pharmaceutical technology platforms [1]. - The company is advancing its proprietary sustained-release drug delivery technology and AI drug discovery platform, which enhances patient compliance by allowing for monthly or longer dosing intervals [2]. Financial Summary - The company's projected revenues for 2025-2027 are estimated at 28.8 billion, 35.9 billion, and 32.5 billion CNY, respectively, with a compound annual growth rate (CAGR) of 24.62% in 2026 [3]. - The net profit attributable to the parent company is forecasted to be 5.34 billion, 7.87 billion, and 6.76 billion CNY for 2025-2027, with corresponding earnings per share (EPS) of 0.46, 0.68, and 0.59 CNY [3]. - The current market capitalization is approximately 112.23 billion HKD, with a total share count of 11,522 million [4].
石药集团（01093）：与阿斯利康合作升级，长效多肽全球布局提速